SCALE 2025 surpassed expectations by bringing together a stellar lineup of industry leaders, top-tier faculty, and innovative companies in aesthetic medicine and dermatology. The event showcased engaging, evidence-based presentations on cutting-edge topics, ranging from topicals and injectables to energy-based devices, regenerative medicine, cellular senescence, and medical dermatology. The symposium featured a hot topics session where many studies and innovations were presented for the first time, reinforcing SCALE’s reputation as a hub for scientific exchange and industry advancement. With robust industry support, lively receptions, and a bustling exhibit hall with more than 140 vendors, SCALE 2025 prepared the way for future growth and collaboration. As one of the founders, Dr. Brian Biesman, noted, “The program featured a world-class faculty and the latest insights, creating an exciting environment that sets the stage for SCALE 2026!”

Adding to the excitement, Dr. Michael Gold reflected, “SCALE 2025 exceeded expectations, bringing together some of the most prominent names in aesthetics and dermatology. The faculty delivered high-quality, engaging presentations, and the exhibit hall was bustling with vendors showcasing the latest innovations. We’re already looking forward to SCALE 2026, scheduled for May 13-17.”

Key Highlights and Industry Insights

Leadership and Panel Discussions

Wendy Lewis moderated a dynamic panel of top CEOs, fostering meaningful discussions about the future of aesthetic medicine. Attendees gained valuable insights into emerging trends, technological advancements, and strategic growth in a rapidly evolving market.

Digital and Online Challenges

One of the most pressing concerns discussed was the challenge aesthetic companies face in managing online content. Technology companies like Google and Meta (the parent company of Facebook and Instagram) exert enormous influence over what consumers see and trust. Their algorithms tend to favor paid advertising, sensational content, and unverified information, making it difficult for trustworthy, science-backed messages to be seen. Navigating these digital platforms requires ongoing strategy, education, and a firm commitment to integrity.

Emerging Therapies and Market Opportunities

A major focus was the rise of GLP-1 therapies, which are revolutionizing patient care. These treatments significantly improve quality of life, but about 37% of GLP-1 patients experience hair loss—a major issue that opens a large market for solutions targeting multiple side effects. Beyond weight management, GLP-1s are also helping with depression, eating disorders, and alcoholism, extending their impact beyond traditional uses. Because these therapies help patients feel and look better, many—around 60%—are motivated to pursue cosmetic procedures to enhance their appearance. This creates a unique opportunity for aesthetic practices to adopt a holistic approach, integrating medical and aesthetic treatments.

Regenerative Medicine and Exosomes

Exosomes continue to be a hot topic, representing a promising frontier in regenerative medicine. While their potential is exciting, the field is fast-moving and still somewhat unstructured. Success will depend on companies making substantial investments in clinical studies that ensure scientific validation and product quality. The future belongs to those delivering clear, evidence-based benefits, with a focus on the contents and cellular effects of exosomes rather than just their quantity. Maintaining transparency and scientific rigor is crucial for responsible advancement.

Personalized Treatments and Consumer Trends

The industry is shifting toward more individualized, tailored aesthetic procedures—matching treatments to patient preferences for customized care. Additionally, the booming skincare market continues to evolve, driven by consumers seeking immediate correction and long-term benefits. Many brands are emphasizing multi-ingredient formulations and scientific validation. The focus is on delivering real, measurable results with science always at the forefront.

Diversity and inclusion are gaining momentum within skincare, reflecting broader societal shifts and consumer demands.

Industry Leadership and Company Highlights

Louis Scafuri (Sofwave) emphasized the importance of understanding social media and Google search algorithms to better connect doctors with patients, building trust and engagement.

Jeff Bedard (Revance) leads a company poised for continued growth. With a CEO experienced in dermatology and a strategic CMO, Adelle Walker, Revance is committed to simplifying business for practitioners and elevating the patient experience. Their portfolio—including Daxxify, RHA by Teoxane, and SkinPen—is gaining recognition, and patient demand is expected to increase.

Jim Hartman (Ourself Skincare) is known for formulations emphasizing multiple active ingredients, delivering both immediate and long-term benefits, all grounded in science.

Mary Fisher (Colorescience) highlighted the company’s double-digit growth, crediting a steadfast focus on consumers and professional partners. Their “Lives Protected” initiative has helped millions adopt daily sun protection routines, reinforcing their leadership in sun care education despite economic challenges.

Drew Taylor, MSc, PhD, (Acorn Biolabs) is pioneering hair follicle banking technology at a young age. Hair loss remains a significant issue—especially among women—and solutions like Acorn’s are poised to meet a widespread demand for improving hair quality and addressing hair loss.

Paul Herchman (GetHairMDT) focuses on innovative hair restoration solutions. With a high demand for hair quality improvement, especially in women, their technology aims to provide new hope for those struggling with hair loss.

Erik Dowell (Aesthelic Management Partners) continues to lead strategic management efforts across aesthetic practices, supporting growth and operational excellence.

The Challenges Ahead

Despite optimism, the industry faces ongoing hurdles. The influence of digital platforms complicates efforts to deliver accurate, science-based information. Looking forward, the industry is moving toward personalized care and stem cell treatments. However, regulatory challenges are increasing—especially concerning treatments by non-physicians. As FDA regulations tighten, prioritizing patient safety, ethical practices, and scientific validation will be essential.

Final Key Takeaways

Be transparent in your messaging and practices.

Leverage your physician partners and include them in your strategies.

Be adaptable—reposition and refine based on market feedback.

Learn from mistakes and pursue continuous improvement.

Strive to be the industry’s best partner, fostering trust and collaboration.

Ultimately, success depends on listening to the market—delivering real solutions, focusing on patient success, and maintaining rigorous scientific standards.